Key PointsOne of CRISPR Therapeutics’ leading pipeline candidates, CTX310, arguably has a larger market opportunity than Casgevy.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.